Financial analysts covering Akebia Therapeutics (traded under the Nasdaq ticker AKBA) have established a consensus twelve-month average price target sitting around 3.75 to 4.00 dollars per share. Individual projections from major Wall Street research firms range from a conservative low target of approximately 1.00 dollar up to an optimistic high target of 6.00 dollars. These forecasts depend heavily on the commercial expansion and prescription uptake of its flagship kidney disease drug Vafseo, ongoing quarterly revenue reports, and clinical development milestones within its pharmaceutical pipeline. Investors are advised to review updated equity research reports to track how market conditions influence these projections.